ALLMedicine™ Keratoacanthoma Center

Mar 30th, 2022 - Treatment with anti-PD1 inhibitors may enhance the risk for developing low grade squamoproliferative skin tumors. Immunohistochemical (IHC) analysis of the immune tumor microenvironment (TME) allows exploration of the pathogenesis and relationship...

Mar 25th, 2022 - Giant Keratoacanthoma of the Hand.|2022|Prezzi T,Heck R,|

Dec 3rd, 2021 - Keratoacanthoma (KA) and well-differentiated cutaneous squamous cell carcinoma (cSCC) are hardly distinguishable clinically and histologically. They both can be seen in patients with hereditary non-polyposis colorectal cancer (HNPCC) or Lynch Synd...

Nov 3rd, 2021 - Squamous cell carcinoma and keratoacanthoma on the neck in a patient with hypohidrotic ectodermal dysplasia.|2021|Suyama T,Shimomura Y,Yoshikawa S,Kamijo T,Komori S,|complications,pathology,complications,pathology,complications,pathology,complicat...

Sep 23rd, 2021 - Debulking followed by intralesional 5-fluorouracil (deb-IL5FU) is a nonsurgical modality which has been used to treat skin cancer anecdotally for many years. There are few in depth studies examining this technique and success rate of intralesional...

Jul 14th, 2021 - The Diagnosis: Cutaneous Angiosarcoma Biopsy revealed a cellular neoplasm consisting of atypical polygonal cells with a hobnailed appearance, vasoformative characteristics, and rare extravasated erythrocytes. The tumor had an infiltrative growth p.

Apr 2nd, 2021 - Transcript: The big impact of MEK inhibitors has been 2-fold. One is that it delays resistance, which you know, you have this additional blockade for cells that have somehow managed to live without BRAF. And so they still need to overcome the ...

Dec 4th, 2020 - Rafael Amado, MD A phase III study comparing trametinib (Mekinist) plus dabrafenib (Tafinlar) with single-agent vemurafenib (Zelboraf) has been stopped early following a positive interim analysis, according to an announcement from GlaxoSmithKline...

Jun 30th, 2020 - Bruno Strigini The combination of dabrafenib (Tafinlar) plus trametinib (Mekinist) has been approved by the European Commission for the treatment of patients with unresectable or metastatic BRAF V600­—positive melanoma, according to a stateme...

Mar 2nd, 2020 - To the Editor: Basal cell carcinoma (BCC) is the most common of the nonmelanoma skin cancers and is a highly curable skin growth. 1,2 Conversely, angiosarcomas are aggressive vascular tumors of endothelial origin that classically appear as reddish.